WO2008080336A1 - Utilisation d'une composition liquide fortement osmotique dans la préparation d'un médicament permettant d'améliorer la cicatrisation - Google Patents
Utilisation d'une composition liquide fortement osmotique dans la préparation d'un médicament permettant d'améliorer la cicatrisation Download PDFInfo
- Publication number
- WO2008080336A1 WO2008080336A1 PCT/CN2007/071264 CN2007071264W WO2008080336A1 WO 2008080336 A1 WO2008080336 A1 WO 2008080336A1 CN 2007071264 W CN2007071264 W CN 2007071264W WO 2008080336 A1 WO2008080336 A1 WO 2008080336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- group
- solution
- molecular weight
- hypertonic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a preparation of a hypertonic liquid composition for preparing a medicine for promoting wound healing
- the method of using the hypertonic solution of the present invention proves that the healing of the wound (anastomotic mouth) can be promoted, which is of positive significance, and the use of a part of hypertonic fluid instead of the isotonic liquid infusion can reduce the amount of infusion after surgery, as in the first embodiment.
- the 500ml infusion can reduce the isotonic infusion to about 1000 ⁇ 1500ml, maintain the circulation function, heart and lung function, and promote the healing of the surgical wound (anastomosis).
- the present applicant discloses a novel pharmaceutical composition, which is disclosed in the patent entitled "Pharmaceutical Composition for Rescue and Preparation Method” and Patent No. 98108902. X, which was filed on May 15, 1998. It is a hypertonic liquid composition and can be widely used in various types of shock, brain trauma, burns, combined injuries, cardiogenic shock caused by right ventricular infarction, hypotension caused by hemodialysis, biliary pancreatitis, surgical patients, Treatment of cardiovascular toxicity and hepatic hydatid disease caused by narcotic drugs. However, this patent does not disclose the effect of the hypertonic fluid composition on promoting wound healing. The entire disclosure of this patent is incorporated herein by reference.
- hypertonic fluid can reduce the inflammatory reaction such as hyperemia and exudation in the wound during the occultation period; it can promote the formation of granulation tissue during the proliferative stage of fibrous tissue, thereby accelerating the healing of the wound.
- the composition of the present invention is used in the preparation of a drug for the treatment of wound healing.
- the composition of the injection is such that the sodium chloride in the composition is not less than 1.5% (w/v), and
- the preferred permeate composition is 4. 2+0. 2 grams of sodium chloride and 7.6 + 0.6 grams of hydroxyethyl starch per 100 ml of liquid.
- At least 10% of the hydroxyethyl starch in the hydroxyethyl starch has a molecular weight of 25,000 to 45,000.
- the molecular weight of the dextran is 40,000-230, 000; the molecular weight of the carboxymethyl starch is 30,000-80,000; the molecular weight of the polyvinylpyrrolidone is 5,000-700,000; the molecular weight of the condensed glucose is 8 , 000-12, 000; sodium alginate has a molecular weight of 20,000 to 2,000, 000; pectin has a molecular weight of 20,000 to 40,000; and pentahydroxyethyl starch has a molecular weight of 264,000.
- the gelatin derivative has a molecular weight of from 20,000 to 3,000,000, which is selected from the group consisting of urea crosslinked gelatin, modified liquid gelatin, oxidized poly gelatin, and degraded gelatin polypeptide.
- the conventional injection solution is selected from the group consisting of water for injection, physiological saline, balance solution, dextrose solution, sodium lactate solution, sodium acetate solution, trishydroxymethylaminomethane solution, and sugar saline.
- the hypertonic solution composition of the present invention is prepared by the following method: 3-18 g selected from the group consisting of hydroxyethyl starch, dextran, carboxymethyl starch, polyvinylpyrrolidone, gelatin derivatives, condensed glucose, glucose, fructose , one or more of lactose, glycerin, xylitol, sodium alginate, N-2-hydroxypropyl acrylamide, ethylene oxide-polypropylene glycol, pectin and pentahydroxyethyl starch are soluble in The total amount is 100 ml selected from one or more mixed water for injection, physiological saline, balanced solution, glucose solution, sodium lactate solution, sodium acetate solution, trishydroxymethylaminomethane solution and aqueous sugar salt solution for conventional injection.
- the hypertonic solution composition of the present invention is used as an infusion during the perioperative period (before, after surgery, after surgery, after surgery), and the administration method is dripping, and preferably, the administration time per 500 ml is 20 ⁇ 60 minutes.
- the dosage to be used depends on the age and weight of the patient. The dosage for adults is usually 250-1500 ml/person/day, and for children, the dosage should be reduced to 100 ml/day or 50 ml/day.
- the use of the hypertonic fluid composition is by intravenous drip or intra-osmotic drip during perioperative procedure.
- the packaging container used in the hyperosmotic liquid pharmaceutical composition of the present invention may be a plastic bag, a plastic bottle, a glass bottle or a glass ampoule.
- the volume of the container can be 20 ml, 50 ml, 100 ml, 250 ml, 370 ml or 500 ml.
- Intravenous (or intraosseous) injection needles and/or infusion tubes, pressure devices, infusion pumps may also be pre-installed or attached to the packaging container.
- FIGS 1A-1E show the results of histopathological examination of the third group of the hypertonic fluid experimental group in Example 12.
- Figure 2 shows normal skin tissue and subcutaneous tissue of SD rats for comparison.
- 3A-3E show the results of histopathological examination of the second group of the Example 12 medium exudate control group.
- 4A-4E show the results of histopathological examination of the fourth group of the hypertonic fluid control group in Example 12.
- 5A-5E show the results of histopathological examination of the fifth group of the hypertonic solution control group in Example 12.
- Polyvinylpyrrolidone (manufactured by Bayer) 12 g
- the pectin is dissolved in a sodium acetate solution, and then sodium chloride is added to dissolve, stir, filter, fill, and sterilize to obtain a hypertonic liquid pharmaceutical composition.
- a hypertonic liquid pharmaceutical composition was prepared according to the ratio of the above formulation.
- a hypertonic liquid pharmaceutical composition was prepared according to the above formulation.
- a hypertonic liquid pharmaceutical composition was prepared according to the above formula according to the method of Example 1, Example 12: Animal test
- Hyperosmotic solution test group 4. 2% sodium chloride / 7.6 % hydroxyethyl starch solution (product of Example 1) was input on the day after surgery, on the first day after surgery, and on the second day after surgery. The dose is 8ml/kg/day, and the speed is 0 ⁇ 4ml/kg/min through the tail vein input;
- Hypertonic solution control group Before anesthesia, before surgery, on the first day after surgery and on the second day after surgery, input 1.5% sodium chloride / 3.0% hydroxyethyl starch solution, the dosage is 24ml/kg / Day, through the tail vein input, speed
- Hypertonic liquid control group Input after anesthesia, on the first day after surgery and on the second day after surgery.
- Figure 1A shows the hypertonic fluid group (Group 3) on the third day after surgery: wounds in SD rats moderately hyperemic, exudative, inflammatory cell infiltration, less necrosis;
- Figure 3A shows the isotonic solution group (Group 2) on the third day after surgery: The wound tissue of SD rats was severely hyperemic, exudative, inflammatory cell infiltration, and more necrotic.
- Figure 1B shows the hypertonic solution group (Group 3) on the 6th day after surgery: granulation tissue hyperplasia and maturation in the wound of SD rats;
- Fig. 3B shows the case of the isotonic solution group (Group 2) on the 6th day after surgery: in which the granulation tissue in the wound of the SD rat was formed, naive, and necrosis was observed.
- Figure 1C shows the hypertonic solution group (Group 3) on the 10th day after surgery: the granulation tissue in the wound of SD rats is mainly fibroblasts;
- Fig. 3C shows the case of the isotonic solution group (Group 2) on the 10th day after surgery: wherein the granulation tissue in the wound of the SD rat is mainly capillary.
- Figure 1D shows the hypertonic solution group (Group 3) on the 15th day after surgery: the scar volume in the wound of the SD rat is small;
- Figure 3D shows the condition of the isotonic solution group (Group 2) on the 15th day after surgery: wherein the scar of the SD rat has a large volume in the wound.
- Figure 1E shows the hypertonic solution group (Group 3) on the 20th day after surgery: the scar in the wound of SD rats is basically absorbed;
- Figure 3E shows the condition of the isotonic solution group (Group 2) on the 20th day after surgery: wherein the SD rats had less scar absorption in the wound.
- Figure 4A shows the hypertonic fluid group (Group 4) on the third day after surgery: wounds in SD rats moderately hyperemic, exudative, inflammatory cell infiltration, less necrosis;
- Figure 4B shows the hypertonic solution group (Group 4) on the 6th day after surgery: granulation tissue proliferation and maturation in the wound of SD rats;
- Figure 4C shows the hypertonic solution group (Group 4) on the 10th day after surgery: The granulation tissue in the wound of SD rats is mainly fibroblasts;
- Figure 4D shows the hypertonic fluid group (Group 4) on the 15th day after surgery: the scar volume in the wound of SD rats is small;
- Figure 4E shows the hypertonic fluid group (Group 4) on the 20th day after surgery: the scar in the wound of SD rats is basically absorbed;
- Figure 5A shows the hypertonic fluid group (Group 5) on the third day after surgery: wounds in SD rats moderately hyperemic, exudative, inflammatory cell infiltration, less necrosis;
- Figure 5B shows the hypertonic solution group (Group 5) on the 6th day after surgery: granulation tissue hyperplasia and maturation in the wound of SD rats;
- Figure 5C shows the hypertonic solution group (Group 5) on the 10th day after surgery: the granulation tissue in the wound of SD rats is mainly fibroblasts;
- Figure 5D shows the hypertonic solution group (Group 5) on the 15th day after surgery: the scar volume in the wound of the SD rat is small;
- Figure 5E shows the hypertonic solution group (Group 5) on the 20th day after surgery: Scars in the wounds of SD rats were substantially absorbed.
- the injection of hypertonic fluid before, during, and after anesthesia can promote the healing of the wound, which is manifested in the occultation period, which can reduce the inflammatory reaction such as hyperemia and exudation in the wound;
- the tissue proliferative phase promotes the formation of granulation tissue, thereby accelerating the healing of the wound.
- the process of change can be seen in the histopathological examination of Figures 1A-1E, 3A-3E, 4A-4E and 5A-5E.
- the comparison of hypertonic and isotonic fluids is shown in Table 1.
- the animal test proves that the high-osmotic liquid pharmaceutical composition of the present invention can promote the healing of surgical wounds as an infusion during the perioperative period.
- the experimental results show that the effect of the hypertonic liquid pharmaceutical composition is superior to that of the isotonic solution.
- hypertonic liquid pharmaceutical composition of the present invention during perioperative use has the advantages of being safe and convenient to use, and can be widely used for various types of surgical wounds or traumatic wounds (faces) and anastomosis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07846090A EP2127659A1 (en) | 2006-12-28 | 2007-12-19 | Use of high osmotic liquid composition in manufacturing medicament for enhancing wound healing |
KR1020097013027A KR20090104811A (ko) | 2006-12-28 | 2007-12-19 | 상처 치료 개선용 약제 제조를 위한 고장액 조성물의 이용 |
JP2009543334A JP2010514707A (ja) | 2006-12-28 | 2007-12-19 | 創傷癒合を促進させる薬物の製造のための高張液組成物の使用 |
BRPI0722078-2A2A BRPI0722078A2 (pt) | 2006-12-28 | 2007-12-19 | Uso de composição de solução hipertônica em fabricação de medicamentos para promover a cicatrização de ferimento |
US12/518,363 US20100136140A1 (en) | 2006-12-28 | 2007-12-19 | A use of hypertonic solution composition in manufacturing medicaments for promoting wound healing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610148145.1 | 2006-12-28 | ||
CN2006101481451A CN101209344B (zh) | 2006-12-28 | 2006-12-28 | 高渗液组合物在制备促进伤口愈合的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008080336A1 true WO2008080336A1 (fr) | 2008-07-10 |
Family
ID=39588149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/071264 WO2008080336A1 (fr) | 2006-12-28 | 2007-12-19 | Utilisation d'une composition liquide fortement osmotique dans la préparation d'un médicament permettant d'améliorer la cicatrisation |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100136140A1 (zh) |
EP (1) | EP2127659A1 (zh) |
JP (1) | JP2010514707A (zh) |
KR (1) | KR20090104811A (zh) |
CN (1) | CN101209344B (zh) |
BR (1) | BRPI0722078A2 (zh) |
WO (1) | WO2008080336A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103006555A (zh) * | 2013-01-05 | 2013-04-03 | 四川美大康佳乐药业有限公司 | 一种羟乙基淀粉注射液及其制备方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101003331B1 (ko) * | 2010-05-11 | 2010-12-23 | 조강선 | 피부 충전제 조성물 |
IL206739A (en) | 2010-06-30 | 2016-06-30 | David Segal | An injectable drug containing silitol as an active substance |
WO2013133873A2 (en) * | 2011-12-04 | 2013-09-12 | Liu David L | Pharmaceutical compositions of sodium ion and calcium ion and methods for treating cancer, tumor and non-malignancy |
CN104644669A (zh) * | 2013-11-19 | 2015-05-27 | 北大方正集团有限公司 | 一种急救用的代血浆药物组合物及其制备方法 |
EP3074026B1 (en) * | 2013-11-25 | 2020-01-08 | D.T.R. Dermal Therapy Research Inc. | Composition, system and method for treating skin |
CN113274360A (zh) * | 2015-09-07 | 2021-08-20 | 持田制药株式会社 | 藻酸冻结干燥制剂 |
DE102016008533A1 (de) * | 2016-07-18 | 2018-01-18 | PlantTec Medical GmbH | Arzneimittel |
WO2018164128A1 (ja) | 2017-03-07 | 2018-09-13 | 持田製薬株式会社 | アルギン酸液剤 |
EA202091396A1 (ru) * | 2017-12-07 | 2020-09-02 | РИВЕН АйПи ХОЛДКО ЭлЭлСи | Композиции и способы лечения метаболических состояний |
DE102018000009A1 (de) * | 2018-01-04 | 2019-03-07 | PlantTec Medical GmbH | Arzneimittel |
WO2021029443A1 (en) * | 2019-08-14 | 2021-02-18 | RIM, Chol Hak | Local hemostatic composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4277463A (en) * | 1978-08-04 | 1981-07-07 | Dobrivoje Tomic | Remedy producing hemostatic and antiphlogistic effects |
CN1235833A (zh) | 1998-05-15 | 1999-11-24 | 赵超英 | 新颖的救治用的药物组合物及其制备方法 |
-
2006
- 2006-12-28 CN CN2006101481451A patent/CN101209344B/zh not_active Expired - Fee Related
-
2007
- 2007-12-19 KR KR1020097013027A patent/KR20090104811A/ko not_active Application Discontinuation
- 2007-12-19 WO PCT/CN2007/071264 patent/WO2008080336A1/zh active Application Filing
- 2007-12-19 BR BRPI0722078-2A2A patent/BRPI0722078A2/pt not_active IP Right Cessation
- 2007-12-19 JP JP2009543334A patent/JP2010514707A/ja active Pending
- 2007-12-19 EP EP07846090A patent/EP2127659A1/en not_active Withdrawn
- 2007-12-19 US US12/518,363 patent/US20100136140A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4277463A (en) * | 1978-08-04 | 1981-07-07 | Dobrivoje Tomic | Remedy producing hemostatic and antiphlogistic effects |
CN1235833A (zh) | 1998-05-15 | 1999-11-24 | 赵超英 | 新颖的救治用的药物组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
ZHAO CHAOYING, CHINESE PRACTICAL SURGERY, vol. 20, 2000, pages 439 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103006555A (zh) * | 2013-01-05 | 2013-04-03 | 四川美大康佳乐药业有限公司 | 一种羟乙基淀粉注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0722078A2 (pt) | 2014-04-01 |
KR20090104811A (ko) | 2009-10-06 |
EP2127659A1 (en) | 2009-12-02 |
US20100136140A1 (en) | 2010-06-03 |
JP2010514707A (ja) | 2010-05-06 |
CN101209344A (zh) | 2008-07-02 |
CN101209344B (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008080336A1 (fr) | Utilisation d'une composition liquide fortement osmotique dans la préparation d'un médicament permettant d'améliorer la cicatrisation | |
US7309502B2 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
EP1465688B9 (en) | Bicarbonate-based solutions for dialysis therapies | |
TWI309569B (en) | Biocompatible dialysis fluids containing icodextrins | |
DK168269B1 (da) | Farmaceutiske præparater indeholdende 3-hydroxysmøresyrederivater og dialyseopløsning, der er egnet til peritoneal dialyse | |
WO2006001962A1 (en) | Bicarbonate-based peritoneal dialysis solutions | |
US5945449A (en) | Sterile bicarbonate concentrate | |
CN111603479A (zh) | 血液净化浓缩物 | |
CN101579307A (zh) | 高渗注射剂在制备促进伤口愈合药物中的用途 | |
Arena | Poisoning—General Treatment and Prevention: Part II | |
RU2567043C1 (ru) | Раствор для перитонеального диализа | |
RU2699967C1 (ru) | Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой | |
RU2382640C1 (ru) | Способ лечения больных с гнойно-воспалительными заболеваниями нижних конечностей на фоне сахарного диабета | |
RU2475234C2 (ru) | Способ профилактики тяжелых осложнений при хирургическом лечении массивных и субмассивных кровопотерь с продолжающимся кровотечением | |
RU2529414C1 (ru) | Способ лечения больных с синдромом внутрипеченочной портальной гипертензии | |
RU2416413C1 (ru) | Средство для лечения кровопотери ("спаскровь") | |
RU2333747C1 (ru) | Композиция для лечения гнойного перитонита у животных | |
RU2293554C1 (ru) | Способ лечения воспалительных заболеваний бронхолегочного аппарата бактериальной этиологии | |
Orgey | A trial of plasma volume expander (haemaccel) in shock | |
Henrich | New therapeutic strategies for acute renal failure in the intensive care unit | |
CN101756989A (zh) | 一种盐酸川芎嗪和苯甲醇的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07846090 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12518363 Country of ref document: US Ref document number: 2007846090 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009543334 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097013027 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0722078 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0722078 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090626 |